Patients thought they had insurance protection. They didn't.
A Parliamentary Standing Committee in India has turned a careful eye toward the quiet suffering embedded in the country's healthcare system — the moment a patient, believing themselves protected by government insurance, discovers that the cost of a scan or a cardiac procedure falls largely on their own shoulders. Without national price ceilings for diagnostic services and with Ayushman Bharat's reimbursement rates frozen in an earlier economic reality, millions of Indians navigate an invisible gap between the promise of coverage and the arithmetic of actual bills. The committee's recommendations — periodic rate revisions, a dedicated device regulator, and direct restitution to overcharged patients — suggest that the architecture of protection must be rebuilt closer to the ground where people actually stand.
- Patients undergoing CT scans, ultrasounds, or blood tests face unpredictable costs that shift by facility and by state, with no national framework to anchor what they should reasonably pay.
- India's flagship insurance scheme, Ayushman Bharat, leaves cardiac, neurosurgical, and interventional patients financing significant portions of their own care because reimbursement rates have not kept pace with market reality.
- High-end medical devices — valves, aortic stents, advanced imaging equipment — remain largely out of reach through subsidized channels, effectively rendering insurance coverage partial at the moments patients need it most.
- The committee is pushing for periodic package rate reviews, a graded penalty system for minor regulatory violations, and a fast-track approval pathway for globally cleared devices — each a lever aimed at easing systemic pressure.
- A structural injustice sits at the center of current enforcement: when companies are penalized for overcharging, recovered funds flow to the government treasury rather than back to the patients who bore the inflated costs.
A Parliamentary Standing Committee has identified a fault line running through India's healthcare safety net — diagnostic tests and imaging services carry no national price ceiling, leaving patients exposed to charges that shift unpredictably depending on where they live and which facility they enter. Some states have imposed temporary controls in moments of crisis, but no overarching framework exists. The committee has urged the health ministry and the Department of Pharmaceuticals to establish uniform pricing, recognizing that diagnostic costs often constitute a decisive share of what patients ultimately pay.
The gaps reach deeper into Ayushman Bharat, the government's flagship insurance program. Evidence submitted by the Sher-i-Kashmir Institute of Medical Sciences illustrated how high-end devices rarely reach patients through subsidized channels. Reimbursement rates for cardiac catheterization, valves, and aortic stents have drifted far below actual market costs, leaving patients to absorb the difference — even those who believed their coverage was secure. Advanced procedures across cardiac surgery, neurosurgery, and interventional radiology continue to be largely self-financed. The committee has called for periodic reviews of these package rates, warning that without revision, the distance between what the scheme promises and what it delivers will only grow.
On the regulatory front, the committee endorsed a graded penalty system to replace criminal charges for minor procedural violations, recommended streamlining licensing and clinical trial costs, and proposed a deemed-approval pathway for devices already cleared by established global regulators. It also suggested raising import duties to give domestic manufacturers a more competitive footing.
Perhaps most pointedly, the committee challenged a quiet injustice in the current enforcement model: when companies are caught overcharging, recovered funds flow to the government treasury rather than to the patients who paid inflated prices. The panel called for stricter preventive enforcement and a direct restitution mechanism — an acknowledgment that reactive penalties do little to repair the financial harm already absorbed by those who could least afford it.
A Parliamentary Standing Committee has identified a critical gap in India's healthcare safety net: diagnostic tests and imaging services operate without any national price ceiling, leaving patients vulnerable to wildly fluctuating charges even when they believe they are covered by government insurance.
The problem is straightforward but consequential. When a patient needs an ultrasound, CT scan, or blood test, the cost can vary dramatically depending on which facility performs it and which state they live in. Some states have imposed temporary caps—RT-PCR testing during the pandemic, for instance—but there is no overarching national framework. The committee has urged the Department of Pharmaceuticals and the health ministry to establish a uniform pricing policy, recognizing that diagnostic expenses often represent a substantial slice of what patients ultimately pay for treatment.
The gaps extend beyond diagnostics into the heart of India's flagship health insurance program. Ayushman Bharat, the government's ambitious scheme to provide coverage for hospital procedures, leaves significant holes in its net. The Sher-i-Kashmir Institute of Medical Sciences submitted evidence showing that high-end medical devices are frequently unavailable through subsidized channels. More troubling, the reimbursement rates embedded in the scheme have not kept pace with actual market costs. Cardiac catheterization procedures, for example, are only partially covered, forcing patients to absorb the remainder themselves. Valves and aortic stents remain prohibitively expensive because the package rates the government reimburses are too low. Advanced devices across multiple specialties—from cardiac surgery to neurosurgery to interventional radiology—continue to be largely self-financed by patients who thought they had insurance protection.
The committee has recommended that these package rates be reviewed and revised periodically, acknowledging that the scheme's pricing structure has drifted away from the reality of what these procedures actually cost. Without such updates, the gap between what Ayushman Bharat promises and what it actually covers will only widen.
On the regulatory side, the committee has endorsed several industry demands that have been pending for years. It called for the introduction of a graded penalty system to replace criminal charges for minor procedural violations, arguing that the current approach is disproportionate. It also recommended streamlining the licensing process, reducing the financial burden of clinical trials, and creating a "deemed approval" pathway for devices that have already been cleared by established global regulators. Under this proposal, such products could receive interim marketing approval within a set timeframe, provided they meet local safety and labeling requirements. The committee also suggested raising import duties on certain devices to help domestic manufacturers compete against low-cost foreign imports.
Perhaps most pointedly, the committee flagged a structural injustice: when companies are caught overcharging patients, the recovered funds go to the government treasury rather than back to the people who were harmed. The panel stressed the need for stricter enforcement to prevent overpricing before it happens, and for a mechanism that ensures patients benefit directly when violations are discovered and remedied. The implication is clear—current enforcement is reactive and does little to ease the financial burden already borne by those who paid inflated prices.
Notable Quotes
The committee urged the Department of Pharmaceuticals and health ministry to formulate a uniform pricing policy for diagnostic services— Parliamentary Standing Committee
Package rates under Ayushman Bharat should be reviewed and revised periodically to reflect prevailing market realities— Parliamentary Standing Committee recommendation
The Hearth Conversation Another angle on the story
Why does a diagnostic test cost so differently depending on where you go?
Because there's no rule saying it can't. A CT scan at one hospital might be half the price of the same scan elsewhere. The committee found that only a few states have ever tried to cap these costs, and only for specific tests during emergencies.
But doesn't Ayushman Bharat cover these things?
It covers some procedures, but the reimbursement rates are frozen in time. A cardiac valve that cost 50,000 rupees five years ago now costs 80,000, but the scheme still reimburses at the old rate. Patients make up the difference.
So the insurance is almost a trap—it makes people think they're protected when they're not.
Not intentionally, but functionally, yes. You're enrolled, you go for surgery, and suddenly you're paying tens of thousands out of pocket for devices the scheme says it covers but doesn't fully fund.
What would actually fix this?
The committee wants regular price reviews, a separate regulator for devices, and—this is important—when companies overcharge and get caught, the money should go back to patients, not the government.
That last part seems obvious.
It does now that you say it. But right now, if a company illegally charges you 100,000 rupees and gets fined, you never see that fine. The government keeps it.
And the domestic manufacturers—why does the committee care about them?
Because if Indian companies can't compete with cheap imports, they'll disappear. Higher import duties would protect them, theoretically. But the real issue is that patients need affordable devices, and right now they're caught between unregulated pricing and limited options.